Boston, MA 06/05/2013 (wallstreetpr) – The shares of Novogen Limited ADR (NASDAQ:NVGN), engaged in consumer health care products had surged by 30.26 percent to close at $5.08 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $3.90 to $5.50 per share during the day. The shares of Novogen Limited ADR (NASDAQ:NVGN) had recorded 52 week high price level of $10.49 per share and 52 week low price level of $1.47 per share.
Novogen Limited ADR (NASDAQ:NVGN) had recently issued ordinary shares at a price of AUD 0.166 per share to facilitate the funding of company’s Phase 1 of CS 6 program, working capital requirements and other corporate costs. Novogen Limited ADR (NASDAQ:NVGN) is primarily focused on pharmaceutical research and development, manufacturing and commercialization of consumer health care products. The company operates its business in three basic segments namely Consumer Business and Wound Healing, Drug Development and Oncology Drug Program.
The shares of Novogen Limited ADR (NASDAQ:NVGN) had recently been surging in their prices and had been experiencing heavy trading volumes in the market. The pharmaceutical research and development company had experienced the trade of nearly 335,341 shares on the last trading session on Tuesday, while the average trading volume of Novogen Limited ADR (NASDAQ:NVGN) is at 30,009 shares per day.
Novogen Limited ADR (NASDAQ:NVGN) presently holds 6.79 million shares outstanding in the market and the institutional ownership in the company is at 1 percent of its holdings.
